Traders Buy Large Volume of Call Options on Eyepoint Pharmaceuticals (NASDAQ:EYPT)

Key Points

• Unusual options activity: Traders purchased 3,011 call options on EyePoint Pharmaceuticals, 19% above the typical daily volume of 2,531 contracts.
• Clinical-trial setback: DURAVYU’s full LUGANO Phase 3 dataset failed to meet its primary endpoint, despite an ad hoc analysis suggesting non-inferiority and a 42% reduction in treatment burden.
• Investor sentiment remains mixed: Cantor Fitzgerald downgraded the stock to “neutral,” while other analysts maintained bullish or neutral ratings. Shares traded near $5.41, compared with a consensus price target of $28.11.

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) saw some unusual options trading activity on Tuesday. Stock traders purchased 3,011 call options on the company. This represents an increase of 19% compared to the typical daily volume of 2,531 call options.

Eyepoint Pharmaceuticals Price Performance

NASDAQ EYPT traded up $0.54 during mid-day trading on Tuesday, hitting $5.41. The company's stock had a trading volume of 9,578,367 shares, compared to its average volume of 1,679,924. Eyepoint Pharmaceuticals has a 52-week low of $3.95 and a 52-week high of $19.11. The stock's fifty day simple moving average is $13.10 and its two-hundred day simple moving average is $13.62. The firm has a market capitalization of $466.40 million, a P/E ratio of -1.44 and a beta of 1.76.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%. The business had revenue of $0.51 million for the quarter, compared to analyst estimates of $0.45 million. On average, equities analysts forecast that Eyepoint Pharmaceuticals will post -3.6 earnings per share for the current fiscal year.

Key Headlines Impacting Eyepoint Pharmaceuticals

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: DURAVYU was reported as non-inferior to aflibercept in an ad hoc analysis that excluded an asymmetric group of nine patients whose vision loss was considered unrelated to wet AMD. The company also highlighted a 42% reduction in treatment burden, favorable safety with redosing, strong anatomic control, and other supportive secondary endpoints. EyePoint LUGANO trial results
• Positive Sentiment: Jefferies maintained a “buy” rating while lowering its price target to $8, implying substantial upside from recent trading levels. Chardan also previously maintained a bullish rating, although its latest view has changed.
• Neutral Sentiment: Trading in EYPT was temporarily halted for pending news before the clinical-trial results were released, reflecting the market significance of the announcement.
• Neutral Sentiment: HC Wainwright reaffirmed its “neutral” rating, while JPMorgan reaffirmed its neutral view. Chardan Capital and RBC also reaffirmed neutral or sector-perform ratings, each assigning a $5 price target.
• Negative Sentiment: The full LUGANO dataset did not achieve the trial’s primary endpoint, a major setback for DURAVYU’s regulatory and commercial prospects. The company may need to explain the impact of the vision-loss cohort and how the remaining Phase 3 program will proceed. Reuters EyePoint trial report
• Negative Sentiment: Cantor Fitzgerald downgraded EyePoint from “overweight” to “neutral,” while multiple analysts have reduced or reaffirmed cautious price targets. Investor discussion has also shifted toward competing ophthalmology companies as potentially stronger opportunities.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Cantor Fitzgerald downgraded shares of Eyepoint Pharmaceuticals from an "overweight" rating to a "neutral" rating in a research note on Monday. Stifel Nicolaus started coverage on Eyepoint Pharmaceuticals in a research note on Thursday, July 16th. They issued a "buy" rating and a $40.00 target price for the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Eyepoint Pharmaceuticals in a research note on Friday, July 17th. Royal Bank Of Canada reaffirmed a "sector perform" rating and set a $5.00 price objective on shares of Eyepoint Pharmaceuticals in a research note on Tuesday. Finally, Guggenheim reiterated a "buy" rating and set a $68.00 price objective on shares of Eyepoint Pharmaceuticals in a report on Wednesday, June 24th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Eyepoint Pharmaceuticals presently has a consensus rating of "Hold" and a consensus price target of $28.11.

Hedge Funds Weigh In On Eyepoint Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. KBC Group NV purchased a new position in Eyepoint Pharmaceuticals in the 1st quarter valued at about $29,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Eyepoint Pharmaceuticals by 51.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company's stock worth $74,000 after purchasing an additional 1,358 shares during the last quarter. Russell Investments Group Ltd. acquired a new position in shares of Eyepoint Pharmaceuticals in the third quarter valued at $76,000. Tower Research Capital LLC TRC raised its stake in shares of Eyepoint Pharmaceuticals by 218.3% in the second quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company's stock worth $82,000 after acquiring an additional 5,967 shares during the last quarter. Finally, California State Teachers Retirement System grew its stake in shares of Eyepoint Pharmaceuticals by 20.6% during the fourth quarter. California State Teachers Retirement System now owns 4,654 shares of the company's stock worth $85,000 after purchasing an additional 794 shares during the period. Hedge funds and other institutional investors own 99.41% of the company's stock.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company's proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint's commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint's lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source